Skip to content
10-K

Annual Report

SUTRO BIOPHARMA, INC. STRO

0001193125-26-119873

← back to feed
Filed
Mar 23, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 16, 2026 16.57M sh
Shares Diluted FY 2025 · Dec 31, 2025 8.5M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 7.74M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$177.23M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$191.54M
Cash And Equivalents FY 2025 · Dec 31, 2025 $58.13M
Cash And Equivalents FY 2025 · Dec 31, 2024 $190.3M
Stockholders Equity FY 2025 · Dec 31, 2025 −$132.45M
Stockholders Equity FY 2025 · Dec 31, 2024 $44.6M
Stockholders Equity FY 2025 · Dec 31, 2023 $149.65M
Current Liabilities FY 2025 · Dec 31, 2025 $75.13M
Current Liabilities FY 2025 · Dec 31, 2024 $131.89M
Total Liabilities FY 2025 · Dec 31, 2025 $306.28M
Total Liabilities FY 2025 · Dec 31, 2024 $342.61M
Current Assets FY 2025 · Dec 31, 2025 $150.93M
Current Assets FY 2025 · Dec 31, 2024 $343.31M
Total Assets FY 2025 · Dec 31, 2025 $173.83M
Total Assets FY 2025 · Dec 31, 2024 $387.21M
Eps Diluted FY 2025 · Dec 31, 2025 −$22.49
Eps Diluted restated FY 2025 · Dec 31, 2024 −$29.40
Eps Basic FY 2025 · Dec 31, 2025 −$22.49
Eps Basic restated FY 2025 · Dec 31, 2024 −$29.40
Sga Expense FY 2025 · Dec 31, 2025 $41.02M
Sga Expense FY 2025 · Dec 31, 2024 $48.45M
Rd Expense FY 2025 · Dec 31, 2025 $166.42M
Rd Expense FY 2025 · Dec 31, 2024 $252.04M
Net Income FY 2025 · Dec 31, 2025 −$191.09M
Net Income FY 2025 · Dec 31, 2024 −$227.46M
Operating Income FY 2025 · Dec 31, 2025 −$158.37M
Operating Income FY 2025 · Dec 31, 2024 −$238.45M
Revenue FY 2025 · Dec 31, 2025 $102.48M
Revenue FY 2025 · Dec 31, 2024 $62.04M